We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Biomarkers in bronchiectasis.
- Authors
Johnson, Emma; Long, Merete B.; Chalmers, James D.
- Abstract
Bronchiectasis is a heterogeneous disease with multiple aetiologies and diverse clinical features. There is a general consensus that optimal treatment requires precision medicine approaches focused on specific treatable disease characteristics, known as treatable traits. Identifying subtypes of conditions with distinct underlying biology (endotypes) depends on the identification of biomarkers that are associated with disease features, prognosis or treatment response and which can be applied in clinical practice. Bronchiectasis is a disease characterised by inflammation, infection, structural lung damage and impaired mucociliary clearance. Increasingly there are available methods to measure each of these components of the disease, revealing heterogeneous inflammatory profiles, microbiota, radiology and mucus and epithelial biology in patients with bronchiectasis. Using emerging biomarkers and omics technologies to guide treatment in bronchiectasis is a promising field of research. Here we review the most recent data on biomarkers in bronchiectasis.
- Subjects
BIOMARKERS; BRONCHIECTASIS; MUCOCILIARY system; INDIVIDUALIZED medicine; BIOLOGY; PROGNOSIS
- Publication
European Respiratory Review, 2024, Vol 33, Issue 173, p1
- ISSN
0905-9180
- Publication type
Article
- DOI
10.1183/16000617.0234-2023